ICYMI, this week we had articles about acne vulgaris management from an expert panel, a look back at summer dermatology conferences, long-term results of roflumilast cream 0.15% for AD, and more.
This Skin Care Awareness Month, Dermatology Times wants to hear your insights. Click here to answer this week's poll.
Catch up on acne vulgaris treatment pearls from Dermatology Times’ most recent Frontline Forum series, featuring James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD.
Researchers found no statistically significant difference between injection techniques.
Endocrine toxic effects were more likely than nonendocrine to become chronic and continue at last follow-up.
Click here to answer this week's acne poll.
Two poster presentations at this year’s Society for Pediatric Dermatology Meeting delve into the psychological impact of the condition and a new option for management.
Dermatology Times is reflecting on this summer's dermatology conferences with a recap of our top 3 articles from Fall Clinical, Maui Derm, World Congress, SDPA, and SPD.
In this week’s Pointers With Portela, the 208SkinDoc takes an in-depth look at Merkel cell carcinoma after Jimmy Buffett passed away from a 4-year battle with the rare form of skin cancer.
Melanoma cases were almost 10 times higher in high Human Development Index countries than in low.
PRP is both safe and effective and may be used as a therapeutic option or alternative in conditions like vitiligo or in wound healing.
The VIOLIN study examined the burden of disease, prevalence, and treatment of vitiligo in patients in France.
A panel of 9 dermatologists met and created 5 statements regarding the role of ceramide-containing skin care products in reducing skin barrier dysfunction related to acne treatments.
Click here to answer this week's skin cancer poll.
Patients treated by rheumatologists were more often treated with tumor necrosis factor inhibitors.
Perifollicular infundibulo-isthmic lymphocytoplasmic infiltrates and fibrosis appeared in all patients, regardless of ethnicity.
As we approach National Eczema Week and National Eczema Month, take a look at the most influential atopic dermatitis research from the last decade.
The review found that utilizing dupilumab to treat these patients with AD cost more than using baricitinib, although dupilumab was more effective.
Roflumilast maintained disease control when patients switched to twice-weekly dosing.
A coprimary end point in the phase 3 LEAP-010 study will not be met.
Significant improvement was shown in erythema and pruritis and patients reported high satisfaction.
BTA treatment was both safe and effective in male and female patients, indicating its potential as a therapeutic strategy in treating Egyptian patients with AGA.
Recipients of the IFundWomen grant kicked off crowdfunding campaigns to grow their businesses.
The condition may present as a manifestation of pediatric rosacea.
Topical minoxidil combined with oral spironolactone significantly improved hair density.
This week’s collection of the latest dermatologic studies covers the hair regrowth cycle in mice, considering large language models in dermatology, cutaneous leiomyosarcomas subtypes, and the efficacy of tralokinumab in older adults with atopic dermatitis.
The physician-owned practice combines residency and Mohs fellowship programs with patient care.
Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.